MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review

Marilena V. Iorio, Carlo M. Croce

Research output: Contribution to journalArticle

951 Citations (Scopus)

Abstract

Early studies have shown how aberrantly expressed microRNAs are a hallmark of several diseases like cancer. MicroRNA expression profiling was shown to be associated with tumour development, progression and response to therapy, suggesting their possible use as diagnostic, prognostic and predictive biomarkers. Moreover, based on the increasing number of studies demonstrating that microRNAs can function as potential oncogenes or oncosuppressor genes, with the goal to improve disease response and increase cure rates, miRNA-based anticancer therapies have recently been exploited, either alone or in combination with current targeted therapies. The advantage of using microRNA approaches is based on its ability to concurrently target multiple effectors of pathways involved in cell differentiation, proliferation and survival. Here, we review our current knowledge about the involvement of microRNAs in cancer, and their potential as diagnostic, prognostic and therapeutic tools.

Original languageEnglish
Pages (from-to)143-159
Number of pages17
JournalEMBO Molecular Medicine
Volume4
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

MicroRNAs
Neoplasms
Therapeutics
Oncogenes
Cell Differentiation
Cell Survival
Biomarkers
Cell Proliferation
Genes

Keywords

  • Biomarkers
  • Diagnostics
  • Human cancer
  • MicroRNAs
  • Therapeutic impact

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

MicroRNA dysregulation in cancer : Diagnostics, monitoring and therapeutics. A comprehensive review. / Iorio, Marilena V.; Croce, Carlo M.

In: EMBO Molecular Medicine, Vol. 4, No. 3, 03.2012, p. 143-159.

Research output: Contribution to journalArticle

@article{111e6c87de394dcc82d0ec31a657d8f9,
title = "MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review",
abstract = "Early studies have shown how aberrantly expressed microRNAs are a hallmark of several diseases like cancer. MicroRNA expression profiling was shown to be associated with tumour development, progression and response to therapy, suggesting their possible use as diagnostic, prognostic and predictive biomarkers. Moreover, based on the increasing number of studies demonstrating that microRNAs can function as potential oncogenes or oncosuppressor genes, with the goal to improve disease response and increase cure rates, miRNA-based anticancer therapies have recently been exploited, either alone or in combination with current targeted therapies. The advantage of using microRNA approaches is based on its ability to concurrently target multiple effectors of pathways involved in cell differentiation, proliferation and survival. Here, we review our current knowledge about the involvement of microRNAs in cancer, and their potential as diagnostic, prognostic and therapeutic tools.",
keywords = "Biomarkers, Diagnostics, Human cancer, MicroRNAs, Therapeutic impact",
author = "Iorio, {Marilena V.} and Croce, {Carlo M.}",
year = "2012",
month = "3",
doi = "10.1002/emmm.201100209",
language = "English",
volume = "4",
pages = "143--159",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - MicroRNA dysregulation in cancer

T2 - Diagnostics, monitoring and therapeutics. A comprehensive review

AU - Iorio, Marilena V.

AU - Croce, Carlo M.

PY - 2012/3

Y1 - 2012/3

N2 - Early studies have shown how aberrantly expressed microRNAs are a hallmark of several diseases like cancer. MicroRNA expression profiling was shown to be associated with tumour development, progression and response to therapy, suggesting their possible use as diagnostic, prognostic and predictive biomarkers. Moreover, based on the increasing number of studies demonstrating that microRNAs can function as potential oncogenes or oncosuppressor genes, with the goal to improve disease response and increase cure rates, miRNA-based anticancer therapies have recently been exploited, either alone or in combination with current targeted therapies. The advantage of using microRNA approaches is based on its ability to concurrently target multiple effectors of pathways involved in cell differentiation, proliferation and survival. Here, we review our current knowledge about the involvement of microRNAs in cancer, and their potential as diagnostic, prognostic and therapeutic tools.

AB - Early studies have shown how aberrantly expressed microRNAs are a hallmark of several diseases like cancer. MicroRNA expression profiling was shown to be associated with tumour development, progression and response to therapy, suggesting their possible use as diagnostic, prognostic and predictive biomarkers. Moreover, based on the increasing number of studies demonstrating that microRNAs can function as potential oncogenes or oncosuppressor genes, with the goal to improve disease response and increase cure rates, miRNA-based anticancer therapies have recently been exploited, either alone or in combination with current targeted therapies. The advantage of using microRNA approaches is based on its ability to concurrently target multiple effectors of pathways involved in cell differentiation, proliferation and survival. Here, we review our current knowledge about the involvement of microRNAs in cancer, and their potential as diagnostic, prognostic and therapeutic tools.

KW - Biomarkers

KW - Diagnostics

KW - Human cancer

KW - MicroRNAs

KW - Therapeutic impact

UR - http://www.scopus.com/inward/record.url?scp=84858126071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858126071&partnerID=8YFLogxK

U2 - 10.1002/emmm.201100209

DO - 10.1002/emmm.201100209

M3 - Article

C2 - 22351564

AN - SCOPUS:84858126071

VL - 4

SP - 143

EP - 159

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 3

ER -